Deerfield Management Company, L.P. (Series C) Silverback Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.37 Billion
- Q3 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 7,503,812 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,503,812
Previous 9,724,508
22.84%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding SBTX
# of Institutions
209Shares Held
83.8MCall Options Held
1.21MPut Options Held
687K-
Ra Capital Management, L.P. Boston, MA10.9MShares$00.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.29MShares$00.0% of portfolio
-
Rubric Capital Management LP New York, NY4.5MShares$00.0% of portfolio
-
Black Rock Inc. New York, NY4.08MShares$00.0% of portfolio
-
Sr One Capital Management, LP4.01MShares$00.0% of portfolio
About Silverback Therapeutics, Inc.
- Ticker SBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,473,800
- Description
- Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...